ReviewHepatology international2018
Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.
Review in Hepatology international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis.Frontiers in medicine · 2021Pooled it
- Challenges in coverage of future hepatitis C vaccines: Review and potential solutions.Vaccine · 2025Review
- Clinical Audit of screening Latent TB, Hepatitis-C, and Occult Hepatitis-B in Rheumatoid arthritis' patients starting biologic or targeted synthetic DMARDS.Pakistan journal of medical sciences · 2025Article
- HCV Co-Infection and Its Genotypic Distribution in HIV-Infected Patients in Nepalese Population.Tropical medicine and infectious disease · 2023Article
- Access to cyclopropanes with geminal trifluoromethyl and difluoromethylphosphonate groups.Beilstein journal of organic chemistry · 2023Article
- Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States.JAMA network open · 2020Article
- Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil.Revista da Sociedade Brasileira de Medicina Tropical · 2020Article
- A changing paradigm: management and treatment of the HCV/HIV-co-infected patient.Hepatology international · 2018Review
- Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C.Adolescent health, medicine and therapeutics · 2018Review
- Providing Hepatitis C Treatment Locally for Substance-Using Patients.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Hepatitis C virus (HCV) treatments have dramatically progressed from poorly tolerated, moderately successful interferon-based therapies to highly effective all-oral interferon-free regimens. While sustained virologic responses have significantly improved with fixed-dose combinations (FDC) of these direct-acting antivirals (DAA), cost remains high and certain populations of patients remain difficult to treat. Glecaprevir (GLE, an NS3/4A protease inhibitor) and pibrentasvir (PIB, NS5A inhibitor) were recently approved as a FDC therapy for HCV, and have expanded reach, reduced cost, and in certain populations, reduced HCV treatment duration. GLE/PIB is effective across all genotypes, and has been shown to be effective in HIV-infected patients, patients with chronic kidney disease, and Child-Pugh A-compensated cirrhosis. GLE/PIB is also effective for a shortened duration of 8 weeks in treatment-naive non-cirrhotic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.